Comparative Study of Therapeutic Efficacy and Safety of Glycolic Acid 6% and Azelaic Acid 20% in Melasma
Not Applicable
- Conditions
- Health Condition 1: L814- Other melanin hyperpigmentation
- Registration Number
- CTRI/2021/06/034044
- Lead Sponsor
- ARULVASAN S S
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patient with clinical diagnosis of facial melasma
Exclusion Criteria
Patients who are non compliance, pregnant, lactating mothers.
Patients who had already undergone other melasma treatment within 6 months.
Patient with known allergy to azelaic acid or glycolic acid
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical improvement in facial melasmaTimepoint: at baseline , 4 weeks and 8weeks
- Secondary Outcome Measures
Name Time Method Improvement in MASI scoreTimepoint: To less than 10%